RxDoctor Payments Data

Asher Imam, DO

Neurology · Southlake, TXNPI 1376602144

Payments from drug & device makers

$36,971in general payments, 2019–2025

Across 1,305 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • SK Life Science, Inc.$4K
  • Inspire Medical Systems, Inc.$2K
  • Abbott$1K
  • Genentech USA, Inc.$1K
  • Livanova USA, Inc.$946
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$3,1509%
  • Speaking & faculty fees$11,42831%
  • Travel & lodging$2,7207%
  • Food & beverage$19,38552%
  • Education$2881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)305$14,492
SK Life Science, Inc.48$3,851
Inspire Medical Systems, Inc.10$1,753
Abbott20$1,440
Genentech USA, Inc.57$1,330
Livanova USA, Inc.11$946
Harmony Biosciences LLC69$879
EMD Serono, Inc.47$816
UCB, Inc.56$806
Lilly USA, LLC45$773
Teva Pharmaceuticals USA, Inc.42$746
Biogen42$728
Jazz Pharmaceuticals Inc.29$605
Grifols USA, LLC41$590
Pfizer58$581
Novartis35$497
Eisai Inc.15$373
Sumitomo Pharma America, Inc.25$354
Lundbeck LLC38$329
Upsher-smith Laboratories LLC24$311
Sanofi11$285
Amgen(2 entities)10$273
AstraZeneca(2 entities)11$269
Axsome Therapeutics, Inc.19$269
Impel Pharmaceuticals Inc.22$239
Merz North America, Inc.12$217
Biohaven Pharmaceuticals, Inc.31$213
Amneal Pharmaceuticals LLC13$212
Sunovion Pharmaceuticals Inc.17$206
Biohaven Pharmaceutical Holding Company Ltd.18$201
Merz Pharmaceuticals, LLC6$133
Argenx US, Inc.6$130
Tanabe Pharma America, Inc.7$129
Regeneron1$123
Azurity Pharmaceuticals, Inc.6$111
Kyowa Kirin, Inc.6$107
Adamas Pharmaceuticals, Inc.6$94
Neurelis, Inc.5$93
Otsuka America Pharmaceutical, Inc.4$88
Impel Pharmaceuticals LLC4$88
Acadia Pharmaceuticals Inc5$84
Assertio Therapeutics, Inc.4$83
Acorda Therapeutics, Inc3$59
Avadel CNS Pharmaceuticals, LLC3$59
Supernus Pharmaceuticals, Inc.3$54
Philips North America LLC2$54
Mallinckrodt Hospital Products Inc.2$48
Merck3$47
Tonix Medicines, Inc.2$45
Mallinckrodt Enterprises LLC2$45
Catalyst Pharmaceuticals, Inc.3$45
Arbor Pharmaceuticals, Inc.3$44
Corium, LLC3$43
Almatica Pharma LLC2$36
ZOLL Respicardia, Inc.2$33
Johnson & Johnson2$33
Avion Pharmaceuticals2$31
Revance Therapeutics, Inc.1$26
MDD US Operations, LLC1$24
GE HealthCare1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,971 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$365,468
Medicare patients
690
Services billed
17,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46100$1,227,766
NourianzIstradefylline25$60,280
BotoxOnabotulinumtoxina37$36,276
Nurtec OdtRimegepant Sulfate15$25,577
BriviactBrivaracetam18$25,554
RytaryCarbidopa/Levodopa32$21,130
RexultiBrexpiprazole12$19,458
Emgality PenGalcanezumab-Gnlm17$12,445
Rivastigmine44$10,442
Pregabalin105$6,422
MyrbetriqMirabegron11$4,866
Sumatriptan Succinate14$4,306
Carbidopa-LevodopaCarbidopa/Levodopa106$3,721
Carbidopa-Levodopa ErCarbidopa/Levodopa58$3,251
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$590$1,227,766100 claims
Kyowa Kirin, Inc.Nourianz$107$60,28025 claims
AbbVieBotox$14,492$36,27637 claims
PfizerNurtec Odt$581$25,57715 claims
UCB, Inc.Briviact$806$25,55418 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$212$22,63155 claims
Otsuka America Pharmaceutical, Inc.Rexulti$88$19,45812 claims
Upsher-smith Laboratories LLCTopiramate$311$64546 claims
Almatica Pharma LLCSertraline Hcl$36$16521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Southlake

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →